Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 4Adenocarcinoma of Lung 1

Interventions

Carboplatin 41Paclitaxel 32Radiotherapy 28Cisplatin 25Bevacizumab 24Erlotinib Hydrochloride 19Pemetrexed 18Docetaxel 16Gemcitabine 15Gefitinib 8Vinorelbine 7Taxes 7Cetuximab 7ceritinib 5Surgical Procedures, Operative 5Etoposide 5Amplified Fragment Length Polymorphism Analysis 5sargramostim 3pembrolizumab 3capmatinib 3Radiotherapy, Conformal 3Radiation 3Gene Expression Profiling 3Cyclophosphamide 32-(1-hexyloxyethyl)-2-devinyl pyropheophorbide-a 3trametinib 2pegfilgrastim 2osimertinib 2Topotecan 2Tirapazamine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Adenocarcinoma of Lung × lazertinib × Clear all
NCT04248829 2026-05-28

Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)

Yuhan Corporation

Phase 3 Completed
393 enrolled 13 charts
Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡